NCT06868667 - Japan Expansion Cohort: Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 28, 2021

Primary Completion Date

April 3, 2024

Study Completion Date

June 19, 2026

Conditions

Multiple Myeloma

Interventions

DRUG

Belantamab mafodotin

Humanized anti-B-cell maturation antigen (BCMA) antibody/drug conjugate.

DRUG

Daratumumab

Anti-cluster of differentiation 38 \[CD-38\] monoclonal antibody.

DRUG

Bortezomib

Proteasome Inhibitor.

DRUG

Dexamethasone

Synthetic glucocorticoid with anti-tumor activity.

Trial Locations (16)

GSK Investigational Site, Aomori

GSK Investigational Site, Fukuoka

GSK Investigational Site, Himeji

GSK Investigational Site, Kamakura

GSK Investigational Site, Kitakyushu

GSK Investigational Site, Kochi

GSK Investigational Site, Matsuyama

GSK Investigational Site, Nagoya

GSK Investigational Site, Okayama

GSK Investigational Site, Osaka

GSK Investigational Site, Ōgaki

GSK Investigational Site, Shibukawa

GSK Investigational Site, Sunto-gun

GSK Investigational Site, Suwa

GSK Investigational Site, Toyohashi

GSK Investigational Site, Yokohama